NCT07390175 Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation
| NCT ID | NCT07390175 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital San Carlos, Madrid |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2025-01-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2025-01-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The mechanisms that maintain persistent atrial fibrillation (AF) in humans remain unknown. In the research project PI18/01268 funded in the previous call for Strategic Action in Health, the group has demonstrated that the hierarchical organization of (i) rotational domains, (ii) frequency domains and (iii) physiological responses to pharmacological provocation with adenosine, allow the identification of domains of high-frequency reentrant activity (hereinafter "DFASI domains") maintainers of AF. As a result, the investigators have developed non-invasive technological models and quantitative indices for the efficient localization of these domains, whose therapeutic approach through ablation has allowed to improve the clinical results of the patients studied, safely without increase in complications (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Likewise, and in response to the objectives of the PI18/01268 project, the investigators have identified hierarchical organization patterns in human ventricular fibrillation (VF) that indicate the existence of universal fibrillatory mechanisms, opening the door to new therapeutic opportunities (Europace 2022;24\[11\]:1788-1799).
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age with persistent AF lasting more than 6 months at the time of the experimental protocol (uninterrupted persistent AF) and clinical indication for an AF ablation procedure. or -Patients over 18 years of age with recurrent VF/VT and poor control with conventional pharmacological measures. Exclusion Criteria: * Lack of patient consent to participate in the study. * In patients with persistent AF, contraindication for the use of adenosine. * AF/VF/VPT secondary to endocrine-metabolic disorders and/or severe systemic disease (thyrotoxicosis, sepsis, pulmonary thromboembolism, etc.). * Contraindications for cardiac catheterization (e.g., intracardiac thrombus). * Impossibility of remote monitoring using an implantable Holter monitor or implantable defibrillator.
Frequently Asked Questions
Who can join the NCT07390175 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07390175 currently recruiting?
Yes, NCT07390175 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hospital San Carlos, Madrid to inquire about joining.
Where is the NCT07390175 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07390175 clinical trial?
NCT07390175 is sponsored by Hospital San Carlos, Madrid. The trial plans to enroll 78 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.